https://mindmedicinelaw.com/briefing/optimi-health-s-clinical-leadership-shift-psilocybin-mdma-trials-in-focus-canada-20260922-44253The Psychedelic Journalen2026-09-22T22:04:59.446043+00:00Optimi Health’s Clinical Leadership Shift: Psilocybin & MDMA Trials in Focus (Canada, 2026)optimi health, psilocybin trials, mdma clinical development, canadian psychedelic regulation, health canada, clinical trial leadership, psychedelic-assisted therapy, drug development strategy, regulatory riskhttps://mindmedicinelaw.com/briefing/va-expands-psilocybin-research-policy-and-access-implications-for-u-s-veterans-20260922-44254The Psychedelic Journalen2026-09-22T22:04:18.197829+00:00VA Expands Psilocybin Research: Policy and Access Implications for U.S. Veteransva psilocybin research, veterans mental health, psychedelic clinical trials, federal policy psychedelics, treatment-resistant depression, ptsd veterans, access to psychedelic therapy, public health innovationhttps://mindmedicinelaw.com/briefing/dmt-harmine-formulation-alters-eeg-microstates-in-controlled-trial-20260922-44177The Psychedelic Journalen2026-09-22T22:04:05.797090+00:00DMT/Harmine Formulation Alters EEG Microstates in Controlled Trialdmt, harmine, eeg microstates, psychedelic brain dynamics, clinical trial design, neural signal diversity, metastability, biomarkers, ayahuasca-inspired formulationhttps://mindmedicinelaw.com/briefing/optimi-health-reshuffles-leadership-in-psychedelic-depression-and-ptsd-trials-20260922-44096The Psychedelic Journalen2026-09-22T15:07:12.815354+00:00Optimi Health Reshuffles Leadership in Psychedelic Depression and PTSD Trialsoptimi health, psychedelic clinical trials, depression research, ptsd treatment, leadership change, health canada, trial design, psilocybin, regulatory strategyhttps://mindmedicinelaw.com/briefing/fda-shifts-from-animal-to-nonclinical-testing-policy-impacts-20260922-43950The Psychedelic Journalen2026-09-22T15:06:20.438983+00:00FDA Shifts from 'Animal' to 'Nonclinical' Testing: Policy Impactsfda policy, nonclinical testing, psychedelic drug development, preclinical safety, animal alternatives, in vitro models, regulatory innovation, clinical trial design, drug approval processhttps://mindmedicinelaw.com/briefing/fda-s-shift-from-animal-to-nonclinical-testing-policy-impact-20260922-43951The Psychedelic Journalen2026-09-22T15:06:03.785237+00:00FDA’s Shift from ‘Animal’ to ‘Nonclinical’ Testing: Policy Impactfda policy, nonclinical testing, animal testing alternatives, psychedelic drug development, preclinical research, regulatory innovation, federal register, drug safety assessment, in vitro methods, neuropsychiatric drug trialshttps://mindmedicinelaw.com/briefing/ketamine-gaba-and-glutamate-new-meta-analysis-in-depression-research-20260921-44189The Psychedelic Journalen2026-09-22T22:05:09.519349+00:00Ketamine, GABA, and Glutamate: New Meta-Analysis in Depression Researchketamine, depression, gaba, glutamate, magnetic resonance spectroscopy, biomarkers, clinical trial design, neurotransmitters, systematic review, psychedelic researchhttps://mindmedicinelaw.com/briefing/5-ht1b-receptor-a-new-focus-in-psychedelic-depression-research-20260921-44178The Psychedelic Journalen2026-09-22T22:04:31.085351+00:005-HT1B Receptor: A New Focus in Psychedelic Depression Researchserotonin 1b receptor, 5-ht1br, depression, anxiety, psychedelic drug development, psilocybin mechanism, clinical trial design, pet biomarkers, neuropharmacologyhttps://mindmedicinelaw.com/briefing/psilocybin-education-demand-among-chronic-pain-patients-in-canada-20260921-43977The Psychedelic Journalen2026-09-22T15:07:28.239621+00:00Psilocybin Education Demand Among Chronic Pain Patients in Canadapsilocybin education, chronic pain, canada, patient survey, public health, mental health comorbidity, cannabis comparison, health equity, psychedelic researchhttps://mindmedicinelaw.com/briefing/psilocybin-for-treatment-resistant-depression-evidence-and-regulatory-outlook-20260921-44011The Psychedelic Journalen2026-09-22T15:06:41.000349+00:00Psilocybin for Treatment-Resistant Depression: Evidence and Regulatory Outlookpsilocybin, treatment-resistant depression, clinical trials, psychedelic therapy, safety profile, regulatory policy, psychological support, mechanism of action, mental health innovationhttps://mindmedicinelaw.com/briefing/ketamine-s-antidepressant-brain-signal-implications-for-u-s-clinical-trials-and--20260921-43777The Psychedelic Journalen2026-09-21T15:06:01.813790+00:00Ketamine’s Antidepressant Brain Signal: Implications for U.S. Clinical Trials and Policyketamine, antidepressant biomarker, brain signal, clinical trials, precision psychiatry, FDA regulation, EEG, treatment-resistant depression, neurobiology, psychedelic researchhttps://mindmedicinelaw.com/briefing/non-hallucinogenic-psilocybin-trial-in-u-s-end-of-life-care-20260921-43776The Psychedelic Journalen2026-09-21T15:05:40.164631+00:00Non-Hallucinogenic Psilocybin Trial in U.S. End-of-Life Carepsilocybin, non-hallucinogenic dosing, end-of-life care, clinical trials, FDA, palliative care, psychedelic therapy, regulatory policy, neuroplasticity, psychoplastogenshttps://mindmedicinelaw.com/briefing/filament-s-pex010-psilocybin-heads-to-phase-3-in-u-s-palliative-care-20260921-43775The Psychedelic Journalen2026-09-21T15:05:18.351245+00:00Filament's PEX010 Psilocybin Heads to Phase 3 in U.S. Palliative Carepsilocybin, filament health, pex010, phase 3 trial, palliative care, psychological distress, fda approval, gmp manufacturing, psychedelic therapy, clinical researchhttps://mindmedicinelaw.com/briefing/fda-expands-cmc-pilot-program-implications-for-psychedelic-drug-sponsors-20260921-43692The Psychedelic Journalen2026-09-21T15:04:59.135765+00:00FDA Expands CMC Pilot Program: Implications for Psychedelic Drug Sponsorsfda cmc pilot, psychedelic drug development, investigational new drug, manufacturing quality, regulatory policy, federal register, clinical trials, expedited review, cbir cder, risk-based regulationhttps://mindmedicinelaw.com/briefing/dea-schedules-diphenidine-as-schedule-i-us-policy-and-research-impact-20260921-43690The Psychedelic Journalen2026-09-21T15:04:34.526456+00:00DEA Schedules Diphenidine as Schedule I: US Policy and Research Impactdea scheduling, diphenidine, schedule i substances, controlled substances act, research restrictions, dissociative drugs, 1971 convention, policy impact, us drug lawhttps://mindmedicinelaw.com/briefing/cell-death-pathways-and-depression-implications-for-psychedelic-therapeutics-20260920-44022The Psychedelic Journalen2026-09-22T15:07:57.284924+00:00Cell Death Pathways and Depression: Implications for Psychedelic Therapeuticscell death pathways, depression neurobiology, neuroinflammation, psychedelic clinical trials, neuroplasticity, biomarkers, antidepressant targets, regulated cell death, mitochondrial dysfunctionhttps://mindmedicinelaw.com/briefing/who-isop-2026-pharmacovigilance-curriculum-global-drug-safety-standards-and-psyc-20260920-43996The Psychedelic Journalen2026-09-22T15:07:42.557799+00:00WHO-ISoP 2026 Pharmacovigilance Curriculum: Global Drug Safety Standards and Psychedelic Medicinepharmacovigilance, who-isop curriculum, psychedelic medicine, drug safety monitoring, regulatory compliance, clinical trials, real-world evidence, risk communication, advanced therapies, public health policyhttps://mindmedicinelaw.com/briefing/ketamine-lidocaine-infusion-pilot-outcomes-in-refractory-neuropathic-pain-2026-s-20260920-44023The Psychedelic Journalen2026-09-22T15:06:58.336644+00:00Ketamine-Lidocaine Infusion: Pilot Outcomes in Refractory Neuropathic Pain (2026, Single-Center Study)ketamine-lidocaine infusion, refractory neuropathic pain, pain biomarkers, pilot clinical trial, intravenous ketamine, chronic pain management, adverse effects, policy implications, biomarker correlation, combination analgesic therapyhttps://mindmedicinelaw.com/briefing/ayahuasca-in-preclinical-depression-models-new-evidence-from-brazil-20260919-43819The Psychedelic Journalen2026-09-21T22:05:32.394579+00:00Ayahuasca in Preclinical Depression Models: New Evidence from Brazilayahuasca, preclinical depression models, serotonergic psychedelics, animal research, bdnf, oxidative stress, translational research, psychedelic regulation, major depressive disorder, maternal deprivationhttps://mindmedicinelaw.com/briefing/first-iv-ketamine-case-for-trd-in-argentinian-public-hospital-20260919-43862The Psychedelic Journalen2026-09-21T22:05:18.993386+00:00First IV Ketamine Case for TRD in Argentinian Public Hospitalketamine, treatment-resistant depression, public hospital, argentina, psychedelic therapy, international adoption, clinical implementation, health policy, risk managementhttps://mindmedicinelaw.com/briefing/ferroptosis-pathways-in-major-depressive-disorder-implications-for-neuropsychiat-20260918-44027The Psychedelic Journalen2026-09-22T15:08:19.041249+00:00Ferroptosis Pathways in Major Depressive Disorder: Implications for Neuropsychiatric Researchferroptosis, major depressive disorder, neuroinflammation, oxidative stress, neuroplasticity, psychedelic research, biomarkers, preclinical models, iron metabolism, antioxidant signalinghttps://mindmedicinelaw.com/briefing/fda-weighs-psychedelic-therapies-as-behavioral-health-groups-push-for-system-rea-20260918-44014The Psychedelic Journalen2026-09-22T15:05:47.121875+00:00FDA Weighs Psychedelic Therapies as Behavioral Health Groups Push for System Readinessfda public hearing, psychedelic therapies, system readiness, behavioral health policy, workforce training, equitable access, clinical implementation, regulatory approval, infrastructure, mental health disparitieshttps://mindmedicinelaw.com/briefing/esketamine-for-perioperative-neuroprotection-clinical-evidence-and-future-direct-20260918-43864The Psychedelic Journalen2026-09-21T22:06:31.144219+00:00Esketamine for Perioperative Neuroprotection: Clinical Evidence and Future Directionsesketamine, perioperative neuroprotection, clinical trials, surgical outcomes, NMDA receptor antagonists, postoperative cognitive dysfunction, anesthesiology, neuroinflammation, public health, regulatory statushttps://mindmedicinelaw.com/briefing/human-myelin-mps-platform-implications-for-ms-and-psychedelic-cns-research-20260918-43875The Psychedelic Journalen2026-09-21T22:06:14.247003+00:00Human Myelin MPS Platform: Implications for MS and Psychedelic CNS Researchmyelin microphysiological system, multiple sclerosis, preclinical CNS models, personalized medicine, psychedelic research, neuroinflammation, demyelinating diseases, drug screening, translational neurosciencehttps://mindmedicinelaw.com/briefing/novel-nocebo-identification-protocol-in-n-of-1-psychedelic-trials-20260918-43856The Psychedelic Journalen2026-09-21T22:06:01.642521+00:00Novel Nocebo Identification Protocol in n-of-1 Psychedelic Trialsnocebo effects, psychedelic clinical trials, balanced placebo design, expectation effects, adverse event attribution, n-of-1 study, trial methodology, safety monitoring, open-blinded crossover, pharmacological effectshttps://mindmedicinelaw.com/briefing/fear-engrams-and-cognitive-dysfunction-new-mechanisms-in-mouse-models-20260918-43863The Psychedelic Journalen2026-09-21T22:05:47.980918+00:00Fear Engrams and Cognitive Dysfunction: New Mechanisms in Mouse Modelsfear engrams, dorsal dentate gyrus, cognitive dysfunction, affective dysfunction, mouse model, stress-related disorders, psychedelic research, neuromodulation, glutamatergic neurons, GABAergic neuronshttps://mindmedicinelaw.com/briefing/validated-short-form-peq-enhances-psychedelic-outcome-research-20260918-43821The Psychedelic Journalen2026-09-21T22:05:04.277778+00:00Validated Short-Form PEQ Enhances Psychedelic Outcome Researchpersisting effects questionnaire, peq-sf, psychedelic outcome measurement, clinical trial assessment, psychometric validation, participant burden, standardized research tools, positive and negative effects, public health data, neuroscience outcomeshttps://mindmedicinelaw.com/briefing/lsd-and-adaptive-stress-pathways-new-mechanistic-insights-from-mouse-prefrontal--20260918-43823The Psychedelic Journalen2026-09-21T22:04:51.493010+00:00LSD and Adaptive Stress Pathways: New Mechanistic Insights from Mouse Prefrontal Cortexlsd, psychedelics, hormesis, prefrontal cortex, adaptive stress, gene expression, neuroscience, clinical translation, risk assessment, psychiatric researchhttps://mindmedicinelaw.com/briefing/structure-based-design-of-subtype-selective-psychedelics-policy-and-research-imp-20260917-44251The Psychedelic Journalen2026-09-22T22:04:43.042203+00:00Structure-Based Design of Subtype-Selective Psychedelics: Policy and Research Impactpsychedelic analogs, structure-based drug design, serotonin receptor subtypes, 5-HT2A selectivity, clinical trial design, regulatory policy, intellectual property, drug scheduling, side effect reductionhttps://mindmedicinelaw.com/briefing/pharmaceutical-management-of-suds-hallucinogens-in-clinical-context-20260917-43840The Psychedelic Journalen2026-09-21T22:06:57.639733+00:00Pharmaceutical Management of SUDs: Hallucinogens in Clinical Contextsubstance use disorder, hallucinogens, psychedelic-assisted therapy, opioid use disorder, pharmaceutical management, clinical trials, precision dosing, biomarkers, harm reduction, translational researchhttps://mindmedicinelaw.com/briefing/ecstatic-phenomena-in-epilepsy-surgery-neural-localization-insights-20260917-43829The Psychedelic Journalen2026-09-21T22:06:46.299658+00:00Ecstatic Phenomena in Epilepsy Surgery: Neural Localization Insightsecstatic seizures, epilepsy surgery, insular cortex, temporal lobe, altered states of consciousness, psychedelic neuroscience, systematic review, neural correlates, clinical research, translational sciencehttps://mindmedicinelaw.com/briefing/systematic-review-cognitive-effects-of-es-ketamine-in-mood-disorders-20260914-43871The Psychedelic Journalen2026-09-22T22:05:25.600342+00:00Systematic Review: Cognitive Effects of (Es)ketamine in Mood Disordersketamine, esketamine, cognitive effects, systematic review, depression, bipolar disorder, clinical safety, FDA, psychiatric treatment, risk-benefit assessment